DOES ANTI-MULLERIAN HORMONE LEVEL VARY AT DIFFERENT RECOMBINANT FSH DOSES?

ANTI-MÜLLERYEN HORMON SEVİYESİ FARKLI RECOMBİNANT FSH DOZLARI İLE DEĞİŞİR Mİ?

Abstract

The aim of this study was to compare intracycle variability of Anti-Mullerian Hormone (AMH) throughout controlled ovarian hyper stimulation (COH) with follicle stimulating hormone (FSH) treatment in women with Polycystic Ovary Syndrome (PCOS) and normoresponder infertile patients. Infertile PCOS (n=30) patients were grouped into two. In the first group 15 patients were treated with long luteal gonadotropin releasing hormone analogue (GnRHa) and invitro fertilization (IVF) and 15 PCOS patients were treated with COH-intrauterine insemination (IUI). Non-PCOS (n=30) patients were treated with COH-IUI. AMH was measured three times in all groups (basal, mid-cycle, luteal). AMH levels in PCOS and non-PCOS patients underwent different amount of exogenous FSH treatment were compared. AMH levels in the PCOS patients were 2-2.5 times higher than non-PCOS patients. Total gonodotropin dose used was higher in the PCOS patients (p

Özet

Bu çalışmanın amacı polikistik over sendromlu (PCOS) ve normoresponder hastalarda follikül stimule edici hormone (FSH) tedavisinin anti-mülleryen hormone (AMH) seviyelerini etkileyip etkilemediğini araştırmaktır. Bu amaçla PCOS'li infertil hastalar (n=30) iki gruba ayrıldı. Birinci gruba long luteal gonodotropin releasing hormon (GnRH) ve invitrofertilizasyon (IVF) (n=15) diğer gruba ise kontrollü overyen hiperstimulasyon ve intrauterin inseminasyon (COH-IUI) tedavisi uygulandı. Normoresponder non-PCOS (n=30) hasta grubu da COH-IUI tedavisi aldı. Tüm gruplarda AMH düzeyleri siklus içinde 3 kez ölçüldü (bazal, midsiklus, luteal). PCOS'li ve non-PCOS'li hastalarda AMH seviyesinin farklı FSH dozlarından etkilenip etkilenmediği araştırıldı. Kullanılan total gonadotropin dozu PCOS'li hastalarda daha yüksekti (p